Giacintia film-coated tablets are indicated in the treatment of major depressive episodes, panic disorder with or without agoraphobia, social anxiety disorders (social phobia), generalized anxiety disorders, obsessive-compulsive disorders.
Active substance: escitalopram;
1 tablet contains 12.77 mg of escitalopram oxalate, which is equivalent to 10 mg of escitalopram;
Excipients: microcrystalline silica cellulose, talc, croscarmellose sodium, magnesium stearate;
Casing: mixture for the Opadry II White film coating: hypromellose (hydroxypropyl methylcellulose); lactose monohydrate; polyethylene glycol; titanium dioxide (E 171).
Hypersensitivity to escitalopram or to other components of the preparation, simultaneous treatment with non-selective, irreversible monoamine oxidase inhibitors (MAOIs) or pimozide.
The safety of doses over 20 mg per day has not been established.
The preparation should be used by adults inside once a day, regardless of food intake.
Major depressive episode. Usually, 10 mg once a day should be prescribed. Depending on the individual sensitivity of the patient, the daily dose can be increased to a maximum of 20 mg.
The antidepressant effect usually occurs within 2-4 weeks. After the disappearance of symptoms, it is necessary to continue treatment for at least 6 months in order to consolidate the effect.
Pregnant
Contraindicated in pregnant women.
Children
Contraindicated in children.
Drivers
Carefully.
Toxicity. Clinical data on escitalopram overdose are limited. Many cases are caused by simultaneous overdose of other preparations. In most cases, mild symptoms or asymptomatic overdose have been reported. Reports of fatal outcomes of escitalopram overdose are sporadic, most of them include concurrent overdose of other medications. Doses of 400-800 mg escitalopram did not cause any severe symptoms.
Symptoms Signs of escitalopram overdose are mainly symptoms from the central nervous system (from dizziness, tremors and agitation to rare cases of serotonin syndrome, seizures and coma), gastrointestinal tract (nausea, vomiting), cardiovascular system (hypotension, tachycardia, prolongation of the QT interval, arrhythmia) and electrolyte / fluid imbalance (hypokalemia, hyponatremia).
Treatment. There is no specific antidote. The proper functioning of the respiratory system should be maintained, adequate oxygenation should be provided. It is possible to use gastric lavage and activated carbon. Monitoring of cardiac and vital signs is recommended along with symptomatic supportive care.
From the hematopoietic and lymphatic system: thrombocytopenia.
From the immune system: anaphylactic reactions.
From the endocrine system: violation of the secretion of antidiuretic hormone.
From the side of nutrition and metabolism: decrease or increase in appetite, increase in body weight; decrease in body weight; hyponatremia, anorexia.
From the side of the psyche: anxiety, restlessness, abnormal dreams, decreased libido in men and women, anorgasmia in women; teeth grinding, agitation, nervousness, panic attacks, confusion; aggression, depersonalization, hallucinations; mania, suicidal thoughts, suicidal behavior.
From the nervous system: insomnia, drowsiness, dizziness, paresthesia, tremor; taste disturbance, sleep disturbance, fainting; serotonin syndrome; dyskinesia, movement disorders, seizures, psychomotor restlessness / akathisia.
From the side of the organs of vision: dilated pupil, blurred vision.
On the part of the hearing organs: ringing in the ears.
On the part of the cardiovascular system: tachycardia; bradycardia; lengthening of the QT interval of the electrocardiogram, orthostatic hypotension.
Respiratory disorders: sinusitis, yawning; nose bleed.
From the gastrointestinal tract: nausea; diarrhea, constipation, vomiting, dry mouth; gastrointestinal bleeding (including rectal).
From the liver and biliary tract: hepatitis, changes in liver function tests.
On the part of the skin and subcutaneous tissue: increased sweating; rash, baldness, hives, itching; bruising, swelling.
From the musculoskeletal system: arthralgia, myalgia.
From the kidneys and urinary tract: urinary retention.
From the reproductive system and mammary glands: men: ejaculation disorders, impotence; priapism; women: metrorrhagia, menorrhagia; galactorrhea.
Escitalopram does not enter into pharmacodynamic or pharmacokinetic interactions with alcohol. However, the combination with alcohol is undesirable.
The simultaneous use of SSRIs and herbal remedies containing St. John's wort can cause an increase in the frequency of adverse reactions.
It is possible to change the effects of anticoagulants due to the simultaneous use with escitalopram. If patients are using oral anticoagulants, it is necessary to carefully monitor the blood coagulation system before and after using escitalopram.
The simultaneous use of non-steroidal anti-inflammatory preparations can increase the tendency to bleeding.
The combination with selegiline (irreversible MAOI type B) requires caution due to the risk of developing serotonin syndrome.
Store in its original packaging at a temperature not exceeding 25 ° C.
Keep out of the reach of children.
Shelf life is 2 years.
There are no reviews for this product.